Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Statements of Operations

v3.25.4
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Income Statement [Abstract]    
Net Revenue $ 6,161,959 $ 9,362,022
Operating expenses:    
Direct costs and expenses 4,226,799 5,983,475
Research and development 1,383,359 1,461,227
Clinical development 705,744 321,655
Selling, general and administrative 9,913,729 9,943,473
Depreciation and amortization 504,836 605,637
Total operating expenses 16,734,467 18,315,467
Loss from operations (10,572,508) (8,953,445)
Other income (expense):    
Interest income 23,385 17,610
Interest expense (44,372) (92,475)
Other income 40,490 10,323
Other expense (502,429) (10,194)
Change in fair value of warrants issued (3,810,278)
Loss before income tax expense (14,865,712) (9,028,181)
Income tax expense (44,042) (11,650)
Net loss $ (14,909,754) $ (9,039,831)
Net loss per common share, basic [1] $ (8.66) $ (22.50)
Net loss per common share, diluted [1] $ (8.66) $ (22.50)
Weighted average common shares outstanding, basic [1] 1,721,082 404,167
Weighted average common shares outstanding, diluted [1] 1,721,082 404,167
[1] The values of Common Stock and paid-in capital, as well as the number of shares issued and outstanding, have been retroactively adjusted in order to give effect to the Company’s 1-for-30 reverse stock split.